Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q33347071

Q33347071

about

Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.Treatment of the elderly patient with diffuse large B cell lymphoma.Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma.Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry.Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

P2860

Q24813078-EA4121CC-A368-4E18-B00C-DF58EB988952 Q33365711-2C7265A8-72A8-4B25-B88A-C5FFD51DF484 Q33383608-4933A7E5-6EAD-4DF7-80C9-C7ACADFD80FE Q33396261-01BACE01-2D60-4604-9A29-EFD6C6B35906 Q33400583-A4BCE7F2-A73E-461E-8B90-03BC83969740 Q33402306-B7EAFBD1-7A42-4D92-9F75-F744611EEDF2 Q33411127-50CEBC64-AFF0-43CC-9DE2-5723B380576F Q33416550-EA1C8171-0C08-450D-87BF-A820A8226EAF Q35705317-F867BA63-5463-4BB8-B0F0-9BC3625EBAAD Q36182830-57B59C22-4FB0-4E6A-BF84-434081B6DBE6 Q37717839-5691F3DB-6CC5-4F46-A3DE-75401C042E5C Q37934952-4AD46692-263C-4F63-81E5-599024543424 Q37998553-0BE1CB7B-CD1F-4860-848F-5E8F1C752DDB Q42165477-58DB0249-E9AA-4B61-B1A3-1F192EA233CB Q44120728-2B042E80-FB3C-4790-AC95-ED80CA293ABD Q45141158-F176DEDA-2D86-4BC8-B524-AB6F71B27F07 Q46658122-A0274C1C-4781-4E3D-B764-70DFCBC1737C Q53828417-28AD4940-BCC8-4416-90E6-88228BB9A1AF

P2860

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q33347071

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu